Fecal Fat - Phospholipids Test · Stool

Most people think of fat in stool as one big lump, either there or not there. But the fats that leave your body in stool are a mix of different molecules, and phospholipids are a specific slice of that mix. When your gut is absorbing fat properly, almost none of these phospholipids show up in stool. When absorption is off, they start appearing in larger amounts.

This test looks at that specific slice. It is a research-oriented measurement rather than a routine screening tool, and it is most often considered when someone has signs of fat malabsorption or a condition known to disrupt fat digestion. The value is in seeing patterns a standard total fecal fat number can flatten out.

What This Test Actually Measures

Phospholipids are fat molecules with a water-friendly head and a water-repelling tail, which lets them form the outer layer of every cell in your body. The phospholipids that pass through your digestive tract come from two main sources: the food you eat (dairy, eggs, meat, fish) and your own bile, which your liver uses to help break down fat.

In a healthy gut, an enzyme in the small intestine breaks down most of these phospholipids so your body can reabsorb the pieces. The ones that reach your stool represent what your digestion did not finish processing. Lab methods that quantify fecal phospholipids typically pull the lipids out of a stool sample, separate them, and measure phosphatidylcholine and lysophosphatidylcholine, the two main forms found in stool.

Cystic Fibrosis and Fat Malabsorption

The clearest human evidence for this biomarker comes from research in children with cystic fibrosis (CF), a genetic condition where thick mucus blocks digestive enzymes from reaching the gut. In a study of children with and without CF, those with CF had markedly higher fecal phosphatidylcholine and lysophosphatidylcholine excretion compared to children without the condition, and this loss paralleled lower overall fat absorption. The elevated phospholipid loss also tracked with disturbances in choline-related metabolism in the blood, suggesting the gut losses have whole-body consequences.

A separate pediatric study of children with CF used the fecal lipid profile, including phospholipids, to group patients by patterns of maldigestion versus malabsorption. Children cluster into distinct groups based on how their bodies handle fats, and these groupings relate to their gut microbiota composition. This supports using fecal phospholipids as part of a broader lipid profile rather than as a single standalone number.

Fatty Liver Disease

A multi-omics study in people with metabolic dysfunction-associated steatotic liver disease (MASLD), the current term for fatty liver not caused by alcohol, found that glycerophospholipid metabolites in stool were strongly linked to the disease. The stool metabolite signature distinguished people with MASLD from healthy controls with high diagnostic accuracy (area under the curve above 0.9, where 1.0 would be a perfect test). This is a research finding, not yet a clinical diagnostic workflow, but it places fecal phospholipids in the conversation around gut-liver communication.

Metabolic Syndrome

A study looking at fecal lipid profiles in people with metabolic syndrome found that this group showed meaningful shifts in fecal lipidomics, including phospholipid-related species, even without signs of intestinal inflammation or a leaky gut barrier. This suggests that changes in how your gut handles phospholipids can appear before classic inflammation-based gut markers turn abnormal.

Reference Ranges

This is a research and exploratory marker. There are no universally standardized clinical cutpoints, and labs that offer the test may report results in slightly different units or formats depending on the method used. Published studies typically compare patient groups against healthy control groups using the lab's own internal standards rather than a single accepted threshold.

Because of this, compare your result within the same lab over time rather than treating any single threshold as absolute. A value that looks high or low in isolation is less useful than a trend collected with the same testing method.

Why One Reading Is Not Enough

Stool-based tests have meaningful day-to-day variability. Research on another stool biomarker, fecal calprotectin, has shown substantial within-person variation, with studies concluding that a change between two samples needs to be quite large before it is clinically meaningful. While this specific finding comes from calprotectin, not phospholipids, the general principle that stool markers fluctuate significantly applies.

Fecal metabolite research also emphasizes that stool composition is strongly affected by collection, storage, and processing methods. If you test once, get a baseline. If you make a dietary or treatment change expected to influence fat absorption, retest in three to six months using the same lab. Then track at least annually as part of a broader gut or metabolic panel.

What to Do With an Abnormal Result

A single high fecal phospholipid result does not diagnose a specific disease. It raises a question worth answering. The most useful next step is to look at the full fecal fat picture: total fecal fat, triglycerides, long-chain fatty acids, and cholesterol in stool, plus pancreatic elastase-1, which reflects how well your pancreas is making digestive enzymes. This combination separates fat loss from weak pancreatic output from fat loss from other causes.

If the pattern suggests pancreatic insufficiency (low elastase alongside elevated fat markers), a gastroenterologist, preferably one who works with pancreatic disease, is the right specialist. If pancreatic function looks preserved but fat loss is real, the workup shifts toward bile flow, intestinal lining health, or microbiome-driven fat handling. Calprotectin can help rule in or out gut inflammation. In people with known or suspected liver disease, the gut-liver axis becomes the relevant frame, and pairing this test with liver markers makes more sense than looking at it alone.

When Results Can Be Misleading

A handful of factors can distort a single reading of this test:

• Collection and storage: stool left at room temperature for hours before processing, or frozen and thawed multiple times, can alter lipid composition. Follow the lab's collection protocol exactly.
• Recent dietary fat: what you ate in the days before collection influences how much phospholipid passes through. Studies of total fecal fat find that a standardized fat intake before collection produces more reliable numbers.
• Recent antibiotics: the gut microbes that help remodel phospholipids shift after antibiotic courses, which can change the fecal lipid profile for weeks afterward.
• Lab method variability: different labs use different extraction and separation techniques. A number from one lab is not directly comparable to a number from another.

How This Fits Into a Fuller Picture

Fecal phospholipids sit inside the larger question of fat digestion, and fat digestion sits inside the still larger question of pancreas, bile flow, gut lining, and microbiome function. Looking at this number alone is like hearing one instrument and trying to guess the rest of the orchestra. Looking at it alongside total fecal fat, pancreatic elastase, short-chain fatty acids, and inflammation markers lets you hear the full piece. This is also why the test is best ordered as part of a comprehensive stool panel rather than in isolation.